Biogen posts solid quarter but pipeline slims ahead of key data for its second controversial Alzheimer's drug

Biogen on Wednesday posted a strong second quarter, and increased its revenue guidance for the rest of the year, which the company said was driven primarily by better-than-expected topline performance and continued cost management.